First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/CTLA4 dual blocker, in patients with advanced solid tumors

[1]  Youpei Lin,et al.  Bispecific antibodies targeting immunomodulatory checkpoints for cancer therapy , 2023, Cancer biology & medicine.

[2]  T. Zhong,et al.  Cadonilimab, a tetravalent PD-1/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity , 2023, mAbs.

[3]  N. Xu,et al.  Efficacy and safety of cadonilimab, an anti-PD-1/CTLA4 bi-specific antibody, in previously treated recurrent or metastatic (R/M) cervical cancer: a multicenter, open-label, single-arm, phase II trial (075) , 2022, Gynecologic Oncology.

[4]  Kongming Wu,et al.  Combination strategies with PD-1/PD-L1 blockade: current advances and future directions , 2022, Molecular cancer.

[5]  A. Korman,et al.  The foundations of immune checkpoint blockade and the ipilimumab approval decennial , 2021, Nature Reviews Drug Discovery.

[6]  B. Monk,et al.  Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Jianji Pan,et al.  Efficacy, safety, and biomarker analysis of Camrelizumab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma (CAPTAIN study) , 2021, Journal for ImmunoTherapy of Cancer.

[8]  Qiwei Tian,et al.  Engineering a Smart Agent for Enhanced Immunotherapy Effect by Simultaneously Blocking PD‐L1 and CTLA‐4 , 2021, Advanced science.

[9]  B. Monk,et al.  Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer. , 2021, Gynecologic oncology.

[10]  P. Ascierto,et al.  Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study. , 2021, The Lancet. Oncology.

[11]  Fenghua Wang,et al.  Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02) , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  M. Ahn,et al.  Safety and Efficacy of Quavonlimab, a Novel Anti-CTLA-4 Antibody (MK-1308), in Combination with Pembrolizumab in First-Line Advanced Non-Small Cell Lung Cancer. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  A. Mansfield,et al.  ID:2908 First-Line Nivolumab + Ipilimumab vs Chemotherapy in Unresectable Malignant Pleural Mesothelioma: CheckMate 743 , 2020 .

[14]  M. Kudo,et al.  Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib , 2020, JAMA oncology.

[15]  B. Baradaran,et al.  Combination of Ipilimumab and Nivolumab in Cancers: From Clinical Practice to Ongoing Clinical Trials , 2020, International journal of molecular sciences.

[16]  Edward S. Kim,et al.  Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer , 2020, JAMA oncology.

[17]  E. Van Cutsem,et al.  Nivolumab plus low-dose ipilimumab as first-line therapy in microsatellite instability-high/DNA mismatch repair deficient metastatic colorectal cancer: Clinical update. , 2020 .

[18]  D. Planchard,et al.  Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic Small-Cell Lung Cancer: Results From the KEYNOTE-028 and KEYNOTE-158 Studies. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[19]  Q. Wei,et al.  Antitumor Activity and Treatment-Related Toxicity Associated With Nivolumab Plus Ipilimumab in Advanced Malignancies: A Systematic Review and Meta-Analysis , 2019, Front. Pharmacol..

[20]  K. Syrigos,et al.  Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. , 2019, The New England journal of medicine.

[21]  A. Rotte,et al.  Combination of CTLA-4 and PD-1 blockers for treatment of cancer , 2019, Journal of Experimental & Clinical Cancer Research.

[22]  A. Italiano,et al.  Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  D. Schadendorf,et al.  Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  D. Schadendorf,et al.  Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. , 2018, The Lancet. Oncology.

[25]  M. Hellmann,et al.  Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032 , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[26]  B. Costello,et al.  Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742). , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Bohuslav Melichar,et al.  Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal‐Cell Carcinoma , 2018, The New England journal of medicine.

[28]  J. Brahmer,et al.  Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary. , 2018, Journal of oncology practice.

[29]  M. Suarez‐Almazor,et al.  Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  J. Wolchok,et al.  Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Chiun Hsu,et al.  Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  S. H. van der Burg,et al.  Anti–CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response , 2014, Science Translational Medicine.

[33]  C. Horak,et al.  Nivolumab plus ipilimumab in advanced melanoma. , 2013, The New England journal of medicine.

[34]  M. Morse,et al.  Update on anti-CTLA-4 antibodies in clinical trials , 2007, Expert opinion on biological therapy.

[35]  J. Woo,et al.  Increase in circulating Foxp3+CD4+CD25high regulatory T cells in nasopharyngeal carcinoma patients , 2007, British Journal of Cancer.

[36]  D. Schadendorf,et al.  Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. , 2019, The New England journal of medicine.

[37]  M. Faham,et al.  Immune Toxicities Elicted by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell Repertoire. , 2017, Cancer research.

[38]  S. Gettinger,et al.  Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. , 2017, The Lancet. Oncology.

[39]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..